166 related articles for article (PubMed ID: 34628929)
21. Variant translocation partners of the anaplastic lymphoma kinase (ALK) gene in two cases of anaplastic large cell lymphoma, identified by inverse cDNA polymerase chain reaction.
Takeoka K; Okumura A; Honjo G; Ohno H
J Clin Exp Hematop; 2014; 54(3):225-35. PubMed ID: 25501114
[TBL] [Abstract][Full Text] [Related]
22. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
24. A case of ALK-positive histiocytosis with multiple lesions in the unilateral breast: A case report.
Kurita A; Yoshida M; Murata T; Yoshida A; Uchiyama N; Takayama S
Int J Surg Case Rep; 2022 Aug; 97():107435. PubMed ID: 35908452
[TBL] [Abstract][Full Text] [Related]
25. Case Report: ALK-Positive Histiocytosis With
Guo Y; Qu HB; Ning G; Jia FL; Liu H; Ma XM; Liao Y
Front Oncol; 2022; 12():858939. PubMed ID: 35359354
[TBL] [Abstract][Full Text] [Related]
26. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Crvenkova S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
[TBL] [Abstract][Full Text] [Related]
27.
Ross JS; Ali SM; Fasan O; Block J; Pal S; Elvin JA; Schrock AB; Suh J; Nozad S; Kim S; Jeong Lee H; Sheehan CE; Jones DM; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Miller VA; Stephens PJ; Gay LM
Oncologist; 2017 Dec; 22(12):1444-1450. PubMed ID: 29079636
[TBL] [Abstract][Full Text] [Related]
28. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
[TBL] [Abstract][Full Text] [Related]
29. Expanding the Phenotype of ALK-positive Histiocytosis: A Report of 2 Cases.
Huang H; Gheorghe G; North PE; Suchi M
Pediatr Dev Pathol; 2018; 21(5):449-455. PubMed ID: 29224419
[TBL] [Abstract][Full Text] [Related]
30. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
[TBL] [Abstract][Full Text] [Related]
31. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
32. Successful Alectinib Treatment for Carcinoma of Unknown Primary with
Sugiyama K; Izumika A; Iwakoshi A; Nishibori R; Sato M; Shiraishi K; Hattori H; Nishimura R; Kitagawa C
Curr Oncol; 2021 May; 28(3):1938-1945. PubMed ID: 34064158
[TBL] [Abstract][Full Text] [Related]
33. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
[TBL] [Abstract][Full Text] [Related]
34. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
35. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
Shi R; Filho SNM; Li M; Fares A; Weiss J; Pham NA; Ludkovski O; Raghavan V; Li Q; Ravi D; Cabanero M; Moghal N; Leighl NB; Bradbury P; Sacher A; Shepherd FA; Yasufuku K; Tsao MS; Liu G
Lung Cancer; 2020 Aug; 146():78-85. PubMed ID: 32521388
[TBL] [Abstract][Full Text] [Related]
36. Local ALK-Positive Histiocytosis With Unusual Morphology and Novel
Tran TAN; Chang KTE; Kuick CH; Goh JY; Chang CC
Int J Surg Pathol; 2021 Aug; 29(5):543-549. PubMed ID: 33243034
[TBL] [Abstract][Full Text] [Related]
37. [Erdheim-Chester disease and Rosai-Dorfman disease: Pathological, radiological and clinical features of adult non-Langerhans cell histiocytosis].
Bösmüller H; Nann D; Horger M; Fend F
Pathologe; 2015 Sep; 36(5):458-66. PubMed ID: 26305142
[TBL] [Abstract][Full Text] [Related]
38. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
39. ALK-Positive Histiocytosis: A Case Report and Literature Review.
Jaber OI; Jarrah DA; Hiasat M; Hussaini MA
Turk Patoloji Derg; 2021; 37(2):172-177. PubMed ID: 33973641
[TBL] [Abstract][Full Text] [Related]
40. ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
Syrykh C; Ysebaert L; Péricart S; Evrard SM; Meggetto F; Kanoun S; Brousset P; Laurent C
Virchows Arch; 2021 Apr; 478(4):779-783. PubMed ID: 33011863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
